133 related articles for article (PubMed ID: 38881902)
61. SIRT1-Mediated Expression of CD24 and Epigenetic Suppression of Novel Tumor Suppressor miR-1185-1 Increases Colorectal Cancer Stemness.
Wang TW; Chern E; Hsu CW; Tseng KC; Chao HM
Cancer Res; 2020 Dec; 80(23):5257-5269. PubMed ID: 33046442
[TBL] [Abstract][Full Text] [Related]
62. Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis.
Duex JE; Owens C; Chauca-Diaz A; Dancik GM; Vanderlinden LA; Ghosh D; Leivo MZ; Hansel DE; Theodorescu D
Cancer Res; 2017 Sep; 77(18):4858-4867. PubMed ID: 28674079
[TBL] [Abstract][Full Text] [Related]
63. Effects of normothermic microwave irradiation on CD44
Asano M; Tanaka S; Sakaguchi M
Biosci Biotechnol Biochem; 2020 Jan; 84(1):103-110. PubMed ID: 31559912
[TBL] [Abstract][Full Text] [Related]
64. CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer.
Yang P; Yu F; Yao Z; Ding X; Xu H; Zhang J
Cancer Immunol Immunother; 2023 Oct; 72(10):3191-3202. PubMed ID: 37418008
[TBL] [Abstract][Full Text] [Related]
65. Effect of curcumin on the cell surface markers CD44 and CD24 in breast cancer.
Calaf GM; Ponce-Cusi R; Abarca-Quinones J
Oncol Rep; 2018 Jun; 39(6):2741-2748. PubMed ID: 29693159
[TBL] [Abstract][Full Text] [Related]
66. Intracellular CD24 disrupts the ARF-NPM interaction and enables mutational and viral oncogene-mediated p53 inactivation.
Wang L; Liu R; Ye P; Wong C; Chen GY; Zhou P; Sakabe K; Zheng X; Wu W; Zhang P; Jiang T; Bassetti MF; Jube S; Sun Y; Zhang Y; Zheng P; Liu Y
Nat Commun; 2015 Jan; 6():5909. PubMed ID: 25600590
[TBL] [Abstract][Full Text] [Related]
67. TGFβ1 Promotes Breast Cancer Local Invasion and Liver Metastasis by Increasing the CD44
Zhang C; Gao H; Li C; Tu J; Chen Z; Su W; Geng X; Chen X; Wang J; Pan W
Technol Cancer Res Treat; 2018 Jan; 17():1533033818764497. PubMed ID: 29658391
[TBL] [Abstract][Full Text] [Related]
68. [Expression, roles and therapy target values of CD24 in oral squamous cell carcinoma].
Mo H; Gao CZ; Wang SJ; Li M; Dong JQ; Yu WD
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Feb; 48(1):16-22. PubMed ID: 26885903
[TBL] [Abstract][Full Text] [Related]
69. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
[TBL] [Abstract][Full Text] [Related]
70. Intracellular CD24 inhibits cell invasion by posttranscriptional regulation of BART through interaction with G3BP.
Taniuchi K; Nishimori I; Hollingsworth MA
Cancer Res; 2011 Feb; 71(3):895-905. PubMed ID: 21266361
[TBL] [Abstract][Full Text] [Related]
71. Integrase-derived peptides together with CD24-targeted lentiviral particles inhibit the growth of CD24 expressing cancer cells.
Shapira S; Finkelshtein E; Kazanov D; Naftali E; Stepansky I; Loyter A; Elbirt D; Hay-Levy M; Brazowski E; Bedny F; Dekel R; Hershkovitz D; Blachar A; Wolf I; Arber N
Oncogene; 2021 Jun; 40(22):3815-3825. PubMed ID: 33958722
[TBL] [Abstract][Full Text] [Related]
72. Engineering nanoparticles boost TNBC therapy by CD24 blockade and mitochondrial dynamics regulation.
Zhao M; Li J; Chen F; Han Y; Chen D; Hu H
J Control Release; 2023 Mar; 355():211-227. PubMed ID: 36736908
[TBL] [Abstract][Full Text] [Related]
73. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.
Bhat-Nakshatri P; Appaiah H; Ballas C; Pick-Franke P; Goulet R; Badve S; Srour EF; Nakshatri H
BMC Cancer; 2010 Aug; 10():411. PubMed ID: 20691079
[TBL] [Abstract][Full Text] [Related]
74. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
[TBL] [Abstract][Full Text] [Related]
75. [Study on the correlation factors on CD44+ CD24-/low ESA+ Lin- cell ratio in breast cancer].
Wang R; Yang XQ; Lü Q
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jan; 45(1):53-6. PubMed ID: 24527582
[TBL] [Abstract][Full Text] [Related]
76. CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder.
Wang X; Liu M; Zhang J; Brown NK; Zhang P; Zhang Y; Liu H; Du X; Wu W; Devenport M; Tao W; Mao-Draayer Y; Chen GY; Chen YE; Zheng P; Liu Y
Cell Metab; 2022 Aug; 34(8):1088-1103.e6. PubMed ID: 35921817
[TBL] [Abstract][Full Text] [Related]
77. CD24 is expressed by myofiber synaptic nuclei and regulates synaptic transmission.
Jevsek M; Jaworski A; Polo-Parada L; Kim N; Fan J; Landmesser LT; Burden SJ
Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6374-9. PubMed ID: 16606832
[TBL] [Abstract][Full Text] [Related]
78. CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model.
Kleinmanns K; Fosse V; Davidson B; de Jalón EG; Tenstad O; Bjørge L; McCormack E
EBioMedicine; 2020 Jun; 56():102783. PubMed ID: 32454402
[TBL] [Abstract][Full Text] [Related]
79. RCD24, B7-H4 and PCNA expression and clinical significance in ovarian cancer.
Zheng C; Yang R
J BUON; 2019; 24(2):715-719. PubMed ID: 31128028
[TBL] [Abstract][Full Text] [Related]
80. CD24+CD44+CD54+EpCAM+ gastric cancer stem cells predict tumor progression and metastasis: clinical and experimental evidence.
Gómez-Gallegos AA; Ramírez-Vidal L; Becerril-Rico J; Pérez-Islas E; Hernandez-Peralta ZJ; Toledo-Guzmán ME; García-Carrancá A; Langley E; Hernández-Guerrero A; López-Casillas F; Herrera-Goepfert R; Oñate-Ocaña LF; Ortiz-Sánchez E
Stem Cell Res Ther; 2023 Feb; 14(1):16. PubMed ID: 36737794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
